Cargando…

Erenumab prevents the occurrence of migraine attacks and not just migraine days: Post-hoc analyses of a phase III study

BACKGROUND: This post-hoc analysis was conducted to evaluate the effect of erenumab on monthly migraine days, monthly migraine attacks, and attack duration in patients with episodic migraine to investigate whether erenumab actually prevents the occurrence of migraine attacks and/or shortens them. ME...

Descripción completa

Detalles Bibliográficos
Autores principales:	Diener, Hans-Christoph, Ashina, Messoud, Ritter, Shannon, Paiva Da Silva Lima, Gabriel, Rasmussen, Soeren, Zielman, Ronald, Tfelt-Hansen, Peer
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2021
Materias:	Brief Reports
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8504413/ https://www.ncbi.nlm.nih.gov/pubmed/33939497 http://dx.doi.org/10.1177/03331024211010308

Ejemplares similares

CGRP in migraine
por: Tfelt-Hansen, Peer, et al.
Publicado: (2009)

Timing and durability of response to erenumab in patients with chronic migraine
por: Tepper, Stewart J., et al.
Publicado: (2021)

Reduction in acute migraine-specific and non-specific medication use in patients treated with erenumab: post-hoc analyses of episodic and chronic migraine clinical trials
por: Tepper, Stewart J, et al.
Publicado: (2021)

Migraine induction with calcitonin gene-related peptide in patients from erenumab trials
por: Christensen, Casper Emil, et al.
Publicado: (2018)

Erenumab in chronic migraine with medication overuse: Subgroup analysis of a randomized trial
por: Tepper, Stewart J., et al.
Publicado: (2019)

Provoked versus spontaneous migraine attacks: pathophysiological similarities and differences
por: Ashina, Håkan, et al.
Publicado: (2022)

Early onset of efficacy with erenumab in patients with episodic and chronic migraine
por: Schwedt, Todd, et al.
Publicado: (2018)

Efficacy of Erenumab for Migraine Prevention in Japanese Patients with Episodic and Chronic Migraine: Results of a Post-Hoc Pooled Analysis
por: Kitamura, Shigekazu, et al.
Publicado: (2023)

Assessment of Erenumab Safety and Efficacy in Patients With Migraine With and Without Aura: A Secondary Analysis of Randomized Clinical Trials
por: Ashina, Messoud, et al.
Publicado: (2021)

The role of erenumab in the treatment of migraine
por: Andreou, Anna P., et al.
Publicado: (2020)

Reversion from chronic migraine to episodic migraine following treatment with erenumab: Results of a post-hoc analysis of a randomized, 12-week, double-blind study and a 52-week, open-label extension
por: Lipton, Richard B, et al.
Publicado: (2020)

Vascular safety of erenumab for migraine prevention
por: Kudrow, David, et al.
Publicado: (2020)

The changing faces of migraine
por: Martelletti, Paolo, et al.
Publicado: (2019)

Prevention of migraine with monoclonal antibodies against CGRP or the CGRP receptor: Addition to the S1 guideline: Therapy of migraine attacks and prevention of migraine. Recommendations of the Germany Society of Neurology and the German Migraine and Headache Society
por: Diener, Hans-Christoph, et al.
Publicado: (2020)

Assessment and characteristics of Erenumab therapy on migraine management
por: Saeed, Haitham, et al.
Publicado: (2022)

Real-world long-term efficacy and safety of erenumab in adults with chronic migraine: a 52-week, single-center, prospective, observational study
por: Cullum, Christopher Kjaer, et al.
Publicado: (2022)

Shaping the future of migraine targeting Calcitonin-Gene-Related-Peptide with the Disease-Modifying Migraine Drugs (DMMDs)
por: Martelletti, Paolo, et al.
Publicado: (2019)

Long‐term efficacy and safety of erenumab in migraine prevention: Results from a 5‐year, open‐label treatment phase of a randomized clinical trial
por: Ashina, Messoud, et al.
Publicado: (2021)

Targeting enkephalins and pituitary adenylate cyclase-activating polypeptide (PACAP) in migraine
por: Ashina, Messoud
Publicado: (2022)

Efficacy and Tolerability of Erenumab for Prevention of Episodic Migraine in India
por: Chowdhury, Debashish, et al.
Publicado: (2022)

Erenumab in the Treatment of Comorbid Trigeminal Neuralgia in Patients With Migraine
por: Katsuki, Masahito, et al.
Publicado: (2023)

Efficacy and safety of eptinezumab in patients with migraine and self-reported aura: Post hoc analysis of PROMISE-1 and PROMISE-2
por: Ashina, Messoud, et al.
Publicado: (2022)

When to use frovatriptan in migraine?
por: Tfelt-Hansen, Peer Carsten
Publicado: (2011)

Prostaglandin E2 induces immediate migraine-like attack in migraine patients without aura
por: Antonova, M, et al.
Publicado: (2013)

Pharmacogenomics and migraine: possible implications
por: Tfelt-Hansen, Peer, et al.
Publicado: (2008)

The chronobiology of migraine: a systematic review
por: Poulsen, Amanda Holmen, et al.
Publicado: (2021)

Long‐term efficacy and safety of erenumab in patients with chronic migraine in whom prior preventive treatments had failed: A subgroup analysis
por: Ashina, Messoud, et al.
Publicado: (2022)

Efficacy and safety of erenumab in women with a history of menstrual migraine
por: Pavlovic, Jelena M., et al.
Publicado: (2020)

Raynaud's phenomenon secondary to erenumab in a patient with chronic migraine
por: Manickam, Agaath Hedina, et al.
Publicado: (2021)

Migraine Prevention with Erenumab: Focus on Patient Selection, Perspectives and Outcomes
por: De Matteis, Eleonora, et al.
Publicado: (2022)

Serum CGRP in migraine patients using erenumab as preventive treatment
por: de Vries Lentsch, Simone, et al.
Publicado: (2022)

Second messenger signalling bypasses CGRP receptor blockade to provoke migraine attacks in humans
por: Do, Thien Phu, et al.
Publicado: (2023)

The K(ATP) channel in migraine pathophysiology: a novel therapeutic target for migraine
por: Al-Karagholi, Mohammad Al-Mahdi, et al.
Publicado: (2017)

Therapeutic novelties in migraine: new drugs, new hope?
por: Do, Thien Phu, et al.
Publicado: (2019)

Long-term safety and tolerability of erenumab: Three-plus year results from a five-year open-label extension study in episodic migraine
por: Ashina, Messoud, et al.
Publicado: (2019)

Guidelines of the International Headache Society for controlled trials of acute treatment of migraine attacks in adults: Fourth edition
por: Diener, Hans-Christoph, et al.
Publicado: (2019)

Brain barriers and their potential role in migraine pathophysiology
por: Wiggers, Astrid, et al.
Publicado: (2022)

Correction to: Therapeutic novelties in migraine: new drugs, new hope?
por: Do, Thien Phu, et al.
Publicado: (2019)

Imaging the inflammatory phenotype in migraine
por: Christensen, Rune Häckert, et al.
Publicado: (2022)

Menstrual migraine is caused by estrogen withdrawal: revisiting the evidence
por: Raffaelli, Bianca, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_4ha34isrvrnbnfh0rhd6avjv8e